Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used

Blood

Volumn 109, Issue 6, 2007, Pages 2643-2648

  Loh, Yvonne ^a   Oyama, Yu ^a   Statkute, Laisvyde ^a   Quigley, Kathleen ^a   Yaung, Kimberly ^a   Gonda, Elizabeth ^a   Barr, Walter ^a   Jovanovic, Borko ^a   Craig, Robert ^a   Stefoski, Dusan ^a   Cohen, Bruce ^b   Burt, Richard K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BLOOD CLOTTING FACTOR 8 INHIBITOR; BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CONTROLLED STUDY; CROHN DISEASE; CYTOPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; WHOLE BODY RADIATION;

EID: 33947271519     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-035766     Document Type: Article

References (60)

1. Horn B, Viele M, Mentzer W, Mogck N, DeSantes K, Cowan M. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant. 1999;24:1009-1013.
2. Hartert A, Willenbacher W, Gunzelmann S, et al. Successful treatment of thrombocytopenia and hemolytic anemia with IvIG in a patient with lupus-like syndrome after mismatched related PBSCT. Bone Marrow Transplant. 2001;27:337-340.
3. O'Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004;127:67-75.
4. Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol. 2004;26:312-314.
5. Marleau AM, Sarvetnick N. T cell homeostasis in tolerance and immunity. J Leukoc Biol. 2005;78:575-584.
6. Poser CM. The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin Neurol Neurosurg. 2006;108:227-233.
7. Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. BMJ. 2002;324:264-266.
8. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295:527-535
9. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102:2373-2378.
10. Burt RK, Georganas C, Schroeder J, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum. 1999;42:2281-2285.
11. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005;128:552-563.
12. Burt RK, Oyama Y, Traynor A, et al. Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: is neoangiogenesis occurring? Bone Marrow Transplant. 2003;32(suppl 1):S65-67.
13. Levitt LJ, Ries CA, Greenberg PL. Pure white-cell aplasia: antibody-mediated autoimmune inhibition of granulopoiesis. N Engl J Med. 1983;308:1141-1146.
14. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88:2983-2992.
15. Hequet O, Salles G, Ketterer N, et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 2003;32:89-95.
16. O'Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004;127:67-75.
17. Lambertenghi-Deliliers GL, Annaloro C, Della Volpe A, Oriani A, Pozzoli E, Soligo D. Multiple autoimmune events after autologous bone marrow transplantation. Bone Marrow Transplant. 1997;19:745-747.
18. + selected peripheral blood cells. Bone Marrow Transplant. 1997;20:697-699.
19. Smith CI, Aarli JA, Biberfeld P, et al. Myasthenia gravis after bone-marrow transplantation: evidence for a donor origin. N Engl J Med. 1983;309:1565-1568.
20. Imamura R, Inoue H, Kato K, et al. Development of rheumatoid arthritis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;30:527-529.
21. Toor AA, Slungaard A, Hedner U, Weisdorf DJ, Key NS. Acquired factor VII deficiency in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2002;29:403-408.
22. Kaloyannidis P, Sakellari I, Fassas A, et al. Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a. Bone Marrow Transplant. 2004;34:187-188.
23. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
24. Trotta F, Bajocchi G, La Corte R, Moratelli S, Sun LY. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 1999;38:1007-1009.
25. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45:200-203.
26. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors: a review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost. 1995;73:1-5.
27. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol. 1998;59:1-4.
28. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881.
29. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset, I: evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985;161:72-87.
30. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
31. + regulatory T cells inhibit the antigen-dependent expansion of self-reactive T cells in vivo. J Immunol. 2006;176:1609-1617.
32. Krupica T Jr, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clin Immunol. Prepublished on June 9, 2006, as DOI 10.1016/j.clim.2006.04.569.
33. Peggs KS, Mackinnon S. Immune reconstitution following haematopoietic stem cell transplantation. Br J Haematol. 2004;124:407-420.
34. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435-442.
35. Michallet MC, Saltel F, Preville X, Flacher M, Revillard JP, Genestier L. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood. 2003;102:3719-3726.
36. Meijer E, Bloem AC, Dekker AW, Verdonck LF. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation. 2003;75:1910-1913.
37. Weimer R, Staak A, Susal C, et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int. 2005;18:226-236.
38. Todd A, Todd J. Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Clin Lab Haematol. 1999;21:69-70.
39. Kaya B, Davies CE, Oakervee HE, Silver NC, Gawler J, Cavenagh JD. Guillain Barre syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia. J Clin Pathol. 2005;58:994-995.
40. Prchal JT, Huang ST, Court WS, Poon MC. Immune hemolytic anemia following administration of antithymocyte globulin. Am J Hematol. 1985;19:95-98.
41. Zomas A, Marsh JC, Harrison NK, et al. Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia. Ann Hematol. 1995;71:49-51.
42. Kawano C, Muroi K, Akioka T, Izumi T, Kodera Y, Ozawa K. Cytomegalovirus pneumonitis, activated prothrombin time prolongation and subacute thyroiditis after unrelated allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;26:1347-1349.
43. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185-191.
44. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens. 1990;35:118-127.
45. DelleKarth G, Laczika K, Scholten C, et al. Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath-1H. Am J Hematol. 1995;50:146-147.
46. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 1996;88:13-19.
47. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. 2003;101:1422-1429. Erratum in: Blood. 2005;105:3018.
48. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002;100:1715-1720.
49. Rutella S, Lemoli RM. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett. 2004;94:11-26.
50. Kubach J, Becker C, Schmitt E, et al. Dendritic cells: sentinels of immunity and tolerance. Int J Hematol. 2005;81:197-203.
51. Johansson S, Berg L, Hall H, Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol. 2005;26:613-618.
52. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691-1695.
53. Otton SH, Turner DL, Frewin R, Davies SV, Johnson SA. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol. 1999;106:261-262.
54. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology. 2004;9:409-411.
55. Food and Drug Administration. FDA alert for healthcare professionals: Alemtuzumab (marketed as Campath). http://www.fda.gov/cder/drug/InfoSheets/HCP/ alemtuzumabHCP.pdf. Accessed June 30, 2006.
56. Raj K, Narayanan S, Augustson B, et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;35:299-301.
57. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340-1346.
58. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
59. Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy. 2001;3:189-195.
60. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484-490.